From MarketBeat:

Dynavax Technologies Co. (NASDAQ:DVAX) CMO Robert Janssen sold 1,500 shares of the stock at an average price of $15.00, totaling $22,500.00. Janssen owns 49,925 shares now valued at approximately $748,875. The sale was disclosed in a filing with the Securities & Exchange Commission.

On Tuesday, October 10th, Robert Janssen sold 1,755 shares of Dynavax Technologies stock. The stock was sold at an average price of $15.01.

Shares of DVAX traded down $0.77 during midday trading on Monday, hitting $13.97. The company has a 1 year low of $9.42 and a 1 year high of $15.15.

Dynavax Technologies had a revenue of $69.51 million during the last quarter. Analysts anticipate that Dynavax Technologies Co. will post -0.12 earnings per share for the current year.

Several brokerages recently issued reports on DVAX. JMP Securities increased their price objective on Dynavax Technologies from $25.00 to $27.00 and gave the stock a “market outperform” rating.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, markets HEPLISAV-B, a vaccine for hepatitis B prevention.



Read more: Dynavax Technologies Co. (NASDAQ:DVAX) CMO Sells $22,500.00 in Stock